Latest Breaking News On - Department of clinical immunology - Page 7 : comparemela.com

XNK Therapeutics appoints Michael Uhlin as Chief Scientific Officer News provided by Share this article STOCKHOLM, April 20, 2021 /PRNewswire/ XNK Therapeutics AB ( XNK ) today announced the appointment of Professor Michael Uhlin as Chief Scientific Officer, effective August 1 st. He will be a member of the company s management team. Michael Uhlin, PhD, will be responsible for defining, implementing, and developing the company s scientific strategy. He will lead a team involved in R&D and manufacturing with focus on platform development as well as improving production processes and executing operational research plans. Professor Uhlin received his master s degree in medical research with a focus on biomedicine from Karolinska Institutet (KI) in 2002 and his PhD in Infection Biology from KI in 2006. Since then, he has held several senior positions primarily within clinical immunology and cellular therapy at KI and Karolinska University Hospital, Stockholm, including serving

Johan liwingMichael uhlinKarolinska university hospitalDepartment of clinical immunologyProfessor michael uhlinChief scientific officerKarolinska institutetInfection biologyClinical immunologyTransfusion medicineKarolinska universityதுறை ஆஃப் மருத்துவ நோயெதிர்ப்புதலைமை அறிவியல் அதிகாரிதொற்று உயிரியல்மருத்துவ நோயெதிர்ப்புபரிமாற்றம் மருந்து